TCGA-L9-A444-01A-21R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.480
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.350
- MYOGENESIS+0.290
- COMPLEMENT+0.280
- IL2_STAT5_SIGNALING+0.260
- KRAS_SIGNALING_UP+0.230
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- MYC_TARGETS_V1-0.620
- MYC_TARGETS_V2-0.550
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.500
- OXIDATIVE_PHOSPHORYLATION-0.470
- MTORC1_SIGNALING-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.430
- DNA_REPAIR-0.420
- PROTEIN_SECRETION-0.420
- TGF_BETA_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.947 |
| 2 | SRR2774280 | — | — | 0.920 |
| 3 | SRR8518409 | — | D | 0.916 |
| 4 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.911 |
| 5 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.911 |
| 6 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.909 |
| 7 | BS_BPSTSCBJ | pilocytic astrocytoma | — | 0.908 |
| 8 | SRR8392886 | — | cohortA1 | 0.908 |
| 9 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.907 |
| 10 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |